{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-082364","form_type":"8-K","ticker":"SEM","cik":"0001320414","company_name":"SELECT MEDICAL HOLDINGS CORP","filed_at":"2023-07-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.556501+00:00","generated_at":"2026-06-13T06:17:31.792345+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Select Medical Q2 estimates: revenue ~$1.67B, Adj EBITDA ~$219M, EPS ~$0.61; in refinancing talks","bullets":["Net operating revenue expected ~$1.67B for Q2 ended June 30, 2023.","Adjusted EBITDA ~$219M; fully diluted EPS ~$0.61.","As of June 30, 2023, cash ~$100M; indebtedness ~$3.75B.","Company in discussions with lenders regarding proposed refinancing of certain debt.","Actual Q2 results to be announced after market close on August 3, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-082364","json":"https://secwatch.observer/filing/0001104659-23-082364.json","markdown":"https://secwatch.observer/filing/0001104659-23-082364.md","text":"https://secwatch.observer/filing/0001104659-23-082364.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1320414/000110465923082364/0001104659-23-082364-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1320414/000110465923082364/tm2321598d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T06:17:31.792345+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c3040fee4f16ffa225eb9fc6854596c725f7d6fb","claim":"SELECT MEDICAL HOLDINGS CORP reported second quarter ended June 30, 2023 results: revenue approximately $1.67 billion, EPS approximately $0.61.","evidence_excerpt":"Select Medical expects its net operating revenue for its second quarter of 2023 to be approximately $1.67 billion. Select Medical expects earnings excluding interest, income taxes, depreciation and amortization, gain (loss) on early retirement of debt, stock compensation expense, gain (loss) on sale of businesses, and equity in earnings (losses) of unconsolidated subsidiaries, or Adjusted EBITDA, for the second quarter of 2023 to be approximately $219 million. Select Medical expects fully diluted earnings per common share for the second quarter of 2023 to be approximately $0.61.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1320414/000110465923082364/0001104659-23-082364-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Revenue","value":"approximately $1.67 billion"},{"label":"EPS","value":"approximately $0.61"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}